These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17366548)

  • 1. A fifteen-year cytogenetic remission following interferon treatment in a patient with an indolent ETV6-ABL positive myeloproliferative syndrome.
    Mozziconacci MJ; Sainty D; Chabannon C
    Am J Hematol; 2007 Jul; 82(7):688-9. PubMed ID: 17366548
    [No Abstract]   [Full Text] [Related]  

  • 2. Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors.
    Nand R; Bryke C; Kroft SH; Divgi A; Bredeson C; Atallah E
    Leuk Res; 2009 Aug; 33(8):1144-6. PubMed ID: 19394693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extramedullary T-lymphoid blast crisis of an ETV6/ABL1-positive myeloproliferative neoplasm with t(9;12)(q34;p13) and t(7;14)(p13;q11.2).
    Yamamoto K; Yakushijin K; Nakamachi Y; Miyata Y; Sanada Y; Tanaka Y; Okamura A; Kawano S; Hayashi Y; Matsuoka H; Minami H
    Ann Hematol; 2014 Aug; 93(8):1435-8. PubMed ID: 24318592
    [No Abstract]   [Full Text] [Related]  

  • 4. Myeloproliferative disorders carrying the t(8;9) (PCM1-JAK2) translocation.
    Bousquet M; Brousset P
    Hum Pathol; 2006 Apr; 37(4):500; author reply 500-2. PubMed ID: 16564930
    [No Abstract]   [Full Text] [Related]  

  • 5. Insertion (12;9)(p13;q34q34): a cryptic rearrangement involving ABL1/ETV6 fusion in a patient with Philadelphia-negative chronic myeloid leukemia.
    Kelly JC; Shahbazi N; Scheerle J; Jahn J; Suchen S; Christacos NC; Mowrey PN; Witt MH; Hostetter A; Meloni-Ehrig AM
    Cancer Genet Cytogenet; 2009 Jul; 192(1):36-9. PubMed ID: 19480935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation.
    Murati A; Gelsi-Boyer V; Adélaïde J; Perot C; Talmant P; Giraudier S; Lodé L; Letessier A; Delaval B; Brunel V; Imbert M; Garand R; Xerri L; Birnbaum D; Mozziconacci MJ; Chaffanet M
    Leukemia; 2005 Sep; 19(9):1692-6. PubMed ID: 16034466
    [No Abstract]   [Full Text] [Related]  

  • 7. A novel ETV6-PDGFRB fusion transcript missed by standard screening in a patient with an imatinib responsive chronic myeloproliferative disease.
    Curtis CE; Grand FH; Waghorn K; Sahoo TP; George J; Cross NC
    Leukemia; 2007 Aug; 21(8):1839-41. PubMed ID: 17508004
    [No Abstract]   [Full Text] [Related]  

  • 8. Identification of a novel ETV6 truncated fusion gene in myeloproliferative neoplasm, unclassifiable with t(4;12)(q12;p13).
    Zhang L; Wang M; Wang Z; Zeng Z; Wen L; Xu Y; Yao L; Cen J; Li H; Pan J; Sun A; Wu D; Chen S; Ma L; Yang X
    Ann Hematol; 2020 Oct; 99(10):2445-2447. PubMed ID: 32734549
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement.
    Tiribelli M; Barraco D; Medeot M; Marin L; Ottaviani E; De Marchi F; Damiani D; Fanin R
    Ann Hematol; 2015 Aug; 94(8):1423-4. PubMed ID: 25900790
    [No Abstract]   [Full Text] [Related]  

  • 10. Molecular cytogenetic findings in a four-way t(1;12;5;12)(p36;p13;q33;q24) underlying the ETV6-PDGFRB fusion gene in chronic myelomonocytic leukemia.
    Crescenzi B; La Starza R; Nozzoli C; Ciolli S; Matteucci C; Romoli S; Rigacci L; Gorello P; Bosi A; Martelli MF; Marynen P; Mecucci C
    Cancer Genet Cytogenet; 2007 Jul; 176(1):67-71. PubMed ID: 17574967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete molecular remission after interferon alpha treatment in a case of 8p11 myeloproliferative syndrome.
    Zhou L; Fu W; Yuan Z; Hou J
    Leuk Res; 2010 Nov; 34(11):e306-7. PubMed ID: 20650528
    [No Abstract]   [Full Text] [Related]  

  • 12. Myeloid/lymphoid neoplasms with eosinophilia/ basophilia and ETV6-ABL1 fusion: cell-of-origin and response to tyrosine kinase inhibition.
    Yao J; Xu L; Aypar U; Meyerson HJ; Londono D; Gao Q; Baik J; Dietz J; Benayed R; Sigler A; Yabe M; Dogan A; Arcila ME; Roshal M; Zhang Y; Mauro MJ; Xiao W
    Haematologica; 2021 Feb; 106(2):614-618. PubMed ID: 32299902
    [No Abstract]   [Full Text] [Related]  

  • 13. ZBTB44-FLT3 fusion in a patient with a myeloproliferative neoplasm.
    Zhou X; Yang C; Zou Z; Lang X; Chen P; Chen S; Wang K; Chen Y; Hao Y; Chen N; Ding J; Li Y; Shen Y; Xiao S
    Br J Haematol; 2020 Oct; 191(2):297-301. PubMed ID: 32866288
    [No Abstract]   [Full Text] [Related]  

  • 14. Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.
    Tefferi A; Levine RL; Kantarjian H
    Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):114-9. PubMed ID: 19147089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALK fusion genes in children with atypical myeloproliferative leukemia.
    Röttgers S; Gombert M; Teigler-Schlegel A; Busch K; Gamerdinger U; Slany R; Harbott J; Borkhardt A
    Leukemia; 2010 Jun; 24(6):1197-200. PubMed ID: 20428197
    [No Abstract]   [Full Text] [Related]  

  • 16. Chronic phase of ETV6-ABL1 positive CML responds to imatinib.
    Kawamata N; Dashti A; Lu D; Miller B; Koeffler HP; Schreck R; Moore S; Ogawa S
    Genes Chromosomes Cancer; 2008 Oct; 47(10):919-21. PubMed ID: 18615681
    [No Abstract]   [Full Text] [Related]  

  • 17. Broad molecular screening of an unclassifiable myeloproliferative disorder reveals an unexpected ETV6/ABL1 fusion transcript.
    Meyer-Monard S; Mühlematter D; Streit A; Chase AJ; Gratwohl A; Cross NC; Jotterand M; Tichelli A
    Leukemia; 2005 Jun; 19(6):1096-9. PubMed ID: 15789067
    [No Abstract]   [Full Text] [Related]  

  • 18. ETV6/GOT1 fusion in a case of t(10;12)(q24;p13)-positive myelodysplastic syndrome.
    Struski S; Mauvieux L; Gervais C; Hélias C; Liu KL; Lessard M
    Haematologica; 2008 Mar; 93(3):467-8. PubMed ID: 18310541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment with imatinib mesylate in a case of chronic myeloproliferative disorder with a t(5;12)(q33;p13.1) without eosinophilia.
    Nadal N; Flandrin P; Cornillon J; Delabesse E; Mauvieux L; Olaru D; Morel S; Campos L
    Cancer Genet Cytogenet; 2006 Sep; 169(2):174-5. PubMed ID: 16938578
    [No Abstract]   [Full Text] [Related]  

  • 20. [Molecular bases of leukemia, MPD and MDS].
    Kitamura T
    Rinsho Ketsueki; 2009 Mar; 50(3):174-81. PubMed ID: 19352084
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.